# FMC Corp: Form 10-Q for the period ended Sep 30, 2019

- Company: [FMC Corp](/companies/fmc.md) (CIK 37785)
- Form: 10-Q
- Filed: 2019-10-30
- Accepted by EDGAR: Oct 30, 2019, 13:30 ET
- Period: 2019-09-30
- Accession: 0000037785-19-000116
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/37785/000003778519000116/fmc-20190930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/37785/000003778519000116/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $1.01bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $3.41bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $581.9m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $1.88bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $432.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $1.53bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $188.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $569.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $159.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | $709.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $8.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $75.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $90.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | $480.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.69 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | $3.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.69 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | $3.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 131,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 132,360,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $65.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $56.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2019-01-01 to 2019-09-30 | $158.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2019-01-01 to 2019-09-30 | $300.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-09-30 | $419.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $4.08bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $9.80bn | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $2.52bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2019-09-30 | $3.03bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2019-09-30 | $379.9m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2019-09-30 | $173.7m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2019-09-30 | $2.65bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2019-09-30 | 129,615,318 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 62,259 characters.

Item 2 of this report contains certain forward-looking statements that are based on our current views and assumptions regarding future events, future business conditions and the outlook for our company based on currently available information.

Whenever possible, we have identified these forward-looking statements by such words or phrases as “will likely result,” “is confident that,” “expect,” “expects,” “should,” “could,” “may,” “will continue to,” “believe,” “believes,” “anticipates,” “predicts,” “forecasts,” “estimates,” “projects,” “potential,” “intends” or similar expressions identifying “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the section “Forward-Looking Information” in Part II of our Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”) and to similar disclaimers in all other reports and forms filed with the Securities and Exchange Commission (“SEC”). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.

We specifically decline to undertake any obligation to publicly revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

### APPLICATION OF CRITICAL ACCOUNTING POLICIES

Our consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles. The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We have described our accounting policies in Note 1 to our consolidated financial statements included in our 2018 Form 10-K. We have reviewed these accounting policies, identifying those that we believe to be critical to the preparation and understanding of our consolidated financial statements. We have reviewed these critical accounting policies with the Audit Committee of our Board of Directors. Critical accounting policies are central to our presentation of results of operations and financial condition and require management to make estimates and judgments on certain matters. We base our estimates and judgments on historical experience, current conditions and other reasonable factors.

The following is a list of those accounting policies that we have deemed most critical to the presentation and understanding of our results of operations and financial condition. See the “Critical Accounting Policies” section in our 2018 Form 10-K for a detailed description of these policies and their potential effects on our results of operations and financial condition.

- Revenue recognition and trade receivables
- Environmental obligations and related recoveries
- Impairment and valuation of long-lived assets and indefinite-lived assets
- Pensions and other postretirement benefits
- Income taxes

### RECENTLY ISSUED AND ADOPTED ACCOUNTING PRONOUNCEMENTS AND REGULATORY ITEMS

See Note 2 to the condensed consolidated financial statements included in this Form 10-Q for a discussion of recently adopted accounting guidance and other new accounting guidance.

### OVERVIEW

We are an agricultural sciences company providing innovative solutions to growers around the world with a robust product portfolio fueled by a market-driven discovery and development pipeline in crop protection, plant health, and professional pest and turf management. We operate in a single distinct business segment and develop, market and sell all three major classes of crop protection chemicals: insecticides, herbicides and fungicides. These products are used in agriculture to enhance crop yield and quality by controlling a broad spectrum of insects, weeds and disease, as well as in non-agricultural markets for pest control.

### Third Quarter 2019 Highlights

The following items are the more significant developments or financial highlights in our business during the three months ended September 30, 2019:

- Revenue of $1,014.3 million for the three months ended September 30, 2019 increased $90.7 million or approximately 10 percent versus the same period last year. A more detailed review of revenue is discussed under the section titled "Results of Operations". On a regional basis, sales in North America decreased by approximately 3 percent, sales in Latin America increased approximately 21 percent, sales in Europe, Middle East and Africa increased by approximately 4 percent, and sales in Asia increased approximately 5 percent. The increase was mostly driven by double-digit organic growth in Brazil, Argentina, France, India, China and Pakistan, as well as price increases across all regions.
- Our gross margin, excluding transaction-related charges, of $432.4 million increased versus the prior year's third quarter by $35.9 million mostly due to higher sales volume. Gross margin percent, excluding transaction-related charges, of approximately 43 percent remained flat compared to approximately 43 percent in the prior year period.
- Selling, general and administrative expenses, excluding transaction-related charges, of $172.3 million decreased approximately 3 percent compared to the prior year period primarily due to cost discipline.
- Research and development expenses of $77.4 million increased $7.3 million or approximately 10 percent.
- Net income (loss) attributable to FMC stockholders increased from $72.8 million to $90.4 million which represents an increase of $17.6 million, or approximately 24 percent. The increase was primarily due to higher margins due to increased sales volume and lower restructuring efforts related to the DuPont Crop Protection Business in the current period partially offset by higher interest expense and the absence of income from discontinued operations related to FMC Lithium.
- Adjusted after-tax earnings from continuing operations attributable to FMC stockholders of $124.2 million increased compared to the prior year amount of $96.7 million primarily due to higher gross margins driven by increased volumes in the current period partially offset by higher interest expense. See the disclosure of our Adjusted Earnings Non-GAAP financial measurement below, under the section titled "Results of Operations".

### RESULTS OF OPERATIONS

### Overview

The following charts provide a reconciliation of Adjusted EBITDA and Adjusted Earnings, both of which are Non-GAAP financial measures, from the most directly comparable GAAP measure. Adjusted EBITDA is provided to assist the readers of our financial statements with useful information regarding our operating results. Our operating results are presented based on how we assess operating performance and internally report financial information. For management purposes, we report operating performance based on earnings before interest, income taxes, and depreciation and amortization, and corporate special charges. Our Adjusted Earnings measure excludes corporate special charges, net of income taxes and discontinued operations attributable to FMC stockholders, net of income taxes. These are excluded by us in the measure we use to evaluate business performance and determine certain performance-based compensation. These items are discussed in detail within the “Other Results of Operations” section that follows. In addition to providing useful information about our operating results to investors, we also believe that excluding the effect of corporate special charges, net of income taxes, and certain Non-GAAP tax adjustments from operating results and discontinued operations allows management and investors to compare more easily the financial performance of our underlying business from period to period. These measures should not be considered as substitutes for net income (loss) or other measures of performance or liquidity reported in accordance with U.S. GAAP.

*(in Millions)*

*(unaudited)*

*(unaudited)*

| 2019 | Three Months Ended September 30, 2018 | 2019 | Nine Months Ended September 30, 2018 |  |
| --- | ---: | ---: | ---: | ---: |
| **Revenue** | $1,014.3 | $923.6 | $3,412.5 | $3,185.9 |
| **Costs and Expenses** |  |  |  |  |
| Costs of sales and services | 581.9 | 528.4 | 1,884.9 | 1,797.8 |
| **Gross margin** | $432.4 | $395.2 | $1,527.6 | $1,388.1 |
| Selling, general and administrative expenses | 188.3 | 194.6 | 569.1 | 587.4 |
| Research and development expenses | 77.4 | 70.1 | 221.7 | 210.9 |
| Restructuring and other charges (income) | 6.8 | 25.4 | 27.3 | 26.4 |
| Total costs and expenses | $854.4 | $818.5 | $2,703.0 | $2,622.5 |
| Income from continuing operations before equity in (earnings) loss of affiliates, non-operating pension and postretirement charges (income), interest expense, net and income taxes (1) | $159.9 | $105.1 | $709.5 | $563.4 |
| Equity in (earnings) loss of affiliates | — | — | — | (0.1) |
| Non-operating pension and postretirement charges (income) | (1.2) | (1.2) | 5.5 | (0.5) |
| Interest expense, net | 41.6 | 33.4 | 115.6 | 101.7 |
| Income (loss) from continuing operations before income taxes | $119.5 | $72.9 | $588.4 | $462.3 |
| Provision (benefit) for income taxes | 8.7 | 22.0 | 75.6 | 81.4 |
| Income (loss) from continuing operations | $110.8 | $50.9 | $512.8 | $380.9 |
| Discontinued operations, net of income taxes | (21.3) | 23.9 | (29.8) | 96.0 |
| **Net income (loss) (GAAP)** | **$89.5** | **$74.8** | **$483.0** | **$476.9** |
| Adjustments to arrive at Adjusted EBITDA: |  |  |  |  |
| Corporate special charges (income): |  |  |  |  |
| Restructuring and other charges (income) (3) | $6.8 | $25.4 | $27.3 | $26.4 |
| Non-operating pension and postretirement charges (income) (4) | (1.2) | (1.2) | 5.5 | (0.5) |
| Transaction-related charges (5) | 16.0 | 18.2 | 52.6 | 134.3 |
| Discontinued operations, net of income taxes | 21.3 | (23.9) | 29.8 | (96.0) |
| Interest expense, net | 41.6 | 33.4 | 115.6 | 101.7 |
| Depreciation and amortization | 36.6 | 37.8 | 111.1 | 111.4 |
| Provision (benefit) for income taxes | 8.7 | 22.0 | 75.6 | 81.4 |
| **Adjusted EBITDA (Non-GAAP) (2)** | **$219.3** | **$186.5** | **$900.5** | **$835.6** |

(1) Referred to as operating profit.

(2) Adjusted EBITDA is defined as operating profit excluding corporate special charges (income) and depreciation and amortization expense.

(3) See Note 10 for details of restructuring and other charges (income).

(4) Our non-operating pension and postretirement charges (income) are defined as those costs (benefits) related to interest, expected return on plan assets, amortized actuarial gains and losses and the impacts of any plan curtailments or settlements. These are excluded from our operating results and are primarily related to changes in pension plan assets and liabilities which are tied to financial market performance and we consider these costs to be outside our operational performance. We continue to include the service cost and amortization of prior service cost in our operating results noted above. These elements reflect the current year operating costs to our business for the employment benefits provided to active employees.

(5) Charges relate to the expensing of the inventory fair value step-up resulting from the application of purchase accounting, transaction costs, costs for transitional employees, other acquired employee related costs, and integration related legal and professional third-party fees. Amounts represent the following:

*(in Millions)*

| DuPont Crop Protection Business Acquisition | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Legal and professional fees (1) | $16.0 | $16.9 | $52.6 | $64.7 |
| Inventory fair value amortization (2) | — | 1.3 | — | 69.6 |
| **Total Transaction-related charges** | **$16.0** | **$18.2** | **$52.6** | **$134.3** |

(1) Represents transaction costs, costs for transitional employees, other acquired employees related costs, and transactional-related costs such as legal and professional third-party fees. These charges are recorded as a component of “Selling, general and administrative expense" on the condensed consolidated statements of income (loss).

(2) These charges are recorded as a component of "Costs of sales and services" on the condensed consolidated statements of income (loss).

*ADJUSTED EARNINGS RECONCILIATION*

*(in Millions)*

| 2019 | Three Months Ended September 30, 2018 | 2019 | Nine Months Ended September 30, 2018 |  |
| --- | ---: | ---: | ---: | ---: |
| **Net income (loss) attributable to FMC stockholders (GAAP)** | $90.4 | $72.8 | $480.6 | $469.7 |
| Corporate special charges (income), pre-tax (1) | 21.6 | 42.4 | 85.4 | 160.2 |
| Income tax (expense) benefit on Corporate special charges (income) (2) | 0.8 | (8.9) | (12.0) | (36.6) |
| Corporate special charges (income), net of income taxes | $22.4 | $33.5 | $73.4 | $123.6 |
| Discontinued operations attributable to FMC Stockholders, net of income taxes | 21.3 | (23.9) | 29.8 | (96.0) |
| Non-GAAP tax adjustments (3) | (9.9) | 14.3 | (10.1) | 18.0 |
| **Adjusted after-tax earnings from continuing operations attributable to FMC stockholders (Non-GAAP)** | **$124.2** | **$96.7** | **$573.7** | **$515.3** |

(1) Represents restructuring and other charges (income), non-operating pension and postretirement charges (income) and transaction-related charges.

(2) The income tax expense (benefit) on corporate special charges (income) is determined using the applicable rates in the taxing jurisdictions in which the corporate special charge (income) occurred and includes both current and deferred income tax expense (benefit) based on the nature of the Non-GAAP performance measure.

(3) We exclude the GAAP tax provision, including discrete items, from the Non-GAAP measure of income, and instead include a Non-GAAP tax provision based upon the annual Non-GAAP effective tax rate. The GAAP tax provision includes certain discrete tax items including, but not limited to: income tax expenses or benefits that are not related to current year ongoing business operations; tax adjustments associated with fluctuations in foreign currency remeasurement of certain foreign operations; certain changes in estimates of tax matters related to prior fiscal years; certain changes in the realizability of deferred tax assets; and changes in tax law which includes the impact of the Act enacted on December 22, 2017. Management believes excluding these discrete tax items assists investors and securities analysts in understanding the tax provision and the effective tax rate related to ongoing operations thereby providing investors with useful supplemental information about FMC's operational performance.

### Results of Operations

For management purposes, Adjusted EBITDA is defined as total revenue less operating expenses (operating expenses consist of costs of sales and services, selling, general and administrative expenses including corporate staff expense, and research and development expenses), excluding depreciation and amortization. We have also excluded the following items from Adjusted EBITDA: interest income and expense associated with corporate debt facilities and investments, income taxes, gains (losses) on divestitures of businesses, restructuring and other charges (income), non-operating pension and postretirement charges (income), investment gains and losses, loss on extinguishment of debt, asset impairments, transaction-related charges, and other income and expense items.

In the discussion below, all comparisons are between the periods unless otherwise noted.

### Revenue

#### Three Months Ended September 30, 2019 vs. 2018

Revenue of $1,014.3 million increased $90.7 million, or approximately 10 percent, versus the prior year quarter. The increase was driven by higher volumes, which contributed approximately 8 percent to the increase, primarily in Latin America, as well as favorable pricing across all regions which impacted revenue by approximately 4 percent. Foreign currency fluctuations had an unfavorable impact on the change in revenue of approximately 2 percent.

#### Nine Months Ended September 30, 2019 vs. 2018

Revenue of $3,412.5 million increased $226.6 million, or approximately 7 percent, versus the prior year period. The increase was driven by higher volumes, which contributed approximately 7 percent to the increase, primarily in Latin America, as well as favorable pricing across all regions which impacted revenue by approximately 4 percent. Foreign currency fluctuations had an unfavorable impact on the change in revenue of approximately 4 percent. The increase in revenue was driven by strong commercial execution and demand for our products. See below for a discussion of revenue by region.

*Total Revenue by Region*

*(in Millions)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| North America | $196.3 | $201.8 | $848.1 | $842.0 |
| Latin America | 460.2 | 379.0 | 923.4 | 737.3 |
| Europe, Middle East & Africa (EMEA) | 138.4 | 133.5 | 854.7 | 826.1 |
| Asia | 219.4 | 209.3 | 786.3 | 780.5 |
| **Total Revenue** | **$1,014.3** | **$923.6** | **$3,412.5** | **$3,185.9** |

#### Three Months Ended September 30, 2019 vs. 2018

North America: Revenue decreased approximately 3 percent versus the prior year period due to reduced demand for our herbicides in the Midwest and Canada as a result of higher channel inventories of those products. These were partially offset by continued share gains for Rynaxypyr® insect control and Cyazypyr® insect control for specialty crops.

Latin America: Revenue increased approximately 21 percent versus the prior year period, or approximately 22 percent excluding foreign currency headwinds, primarily due to strong volume growth and price increases in Brazil. Price increase in Brazil and continued high demand for applications on cotton and Boral® herbicide and Rynaxypyr® insect control on sugarcane in Brazil more than offset the foreign currency impact on revenues.

Europe, Middle East & Africa ("EMEA"): Revenue increased approximately 4 percent versus the prior year period, or approximately 8 percent excluding foreign currency headwinds, primarily due to the successful launch of Battle® Delta herbicides and Cyazypyr® insect control registration extensions.

Asia: Revenue increased approximately 5 percent versus the prior year period, or approximately 9 percent excluding foreign currency headwinds, primarily due to continued strong growth in India, driven by demand for both Rynaxypyr® insect control and Cyazypyr® insect control, as well as in China and Pakistan.

#### Nine Months Ended September 30, 2019 vs. 2018

North America: Revenue increased approximately 1 percent versus the prior year period due to strong sales of Rynaxypyr® insect control for tree fruits and vegetables and the launch of Lucento® fungicide. These were almost offset by extreme weather and flooding during the period.

Latin America: Revenue increased approximately 25 percent versus the prior year period, or approximately 29 percent excluding foreign currency headwinds, primarily due to Brazil. Increased cotton acreage as well as a boll weevil infestation drove strong demand in Brazil for cotton insecticides. Additionally, demand for herbicides in sugarcane, as well as robust demand for our insecticides in soybean applications contributed to the increase in revenue.

Europe, Middle East & Africa: Revenue increased approximately 3 percent versus the prior year period, or approximately 10 percent excluding foreign currency headwinds, primarily due to the successful launch of Battle® Delta herbicides and Cyazypyr® insect control registrations across the region. Favorable weather, demand for our diamide products, and higher pricing throughout the region also contributed. These increases were partially offset by unfavorable foreign currency impacts.

Asia: Revenue increased approximately 1 percent versus the prior year period, or approximately 7 percent excluding foreign currency headwinds, primarily driven by continued strong growth in India and new products across the region. Almost offsetting the increases were adverse weather conditions in Australia and challenged rice markets in China.

In late March, there was an explosion within an industrial park in China which impacted one plant operated by one of our contract manufacturing tollers. The local government has temporarily shut down the entire park to investigate the cause of the explosion. We are expecting production to restart in the fourth quarter of 2019. Our global manufacturing network provides significant supply chain flexibility. Due to the strength of our partnerships and our alternate sourcing options, we believe we can continue to secure supply of the active ingredients normally manufactured at this location as needed.

For 2019, full-year revenue is expected to be in the range of approximately $4.58 billion to $4.62 billion.

### Gross margin

#### Three Months Ended September 30, 2019 vs. 2018

Gross margin of $432.4 million increased $37.2 million, or approximately 9 percent versus the prior year quarter. Gross margin, excluding transaction-related charges, increased versus the prior year quarter by $35.9 million. The increase was primarily due to the higher revenues which were driven by increased volumes and pricing, partially offset by higher costs, primarily raw material costs.

Gross margin percent of approximately 43 percent remained flat as compared to the prior year period primarily due to higher pricing, offset by higher costs primarily driven by raw material costs. Gross margin percent, excluding transaction-related charges, also remained flat at approximately 43 percent.

#### Nine Months Ended September 30, 2019 vs. 2018

Gross margin of $1,527.6 million increased $139.5 million, or approximately 10 percent versus the prior year period. Gross margin, excluding transaction-related charges, also increased versus the prior year period by $69.9 million. The increase was primarily due to the higher revenues which were driven by increased volumes and pricing, partially offset by higher costs, primarily raw material costs.

Gross margin percent of approximately 45 percent slightly increased from approximately 44 percent in the prior year period. The increase from higher pricing was nearly offset by higher costs, primarily raw material costs. Gross margin percent, excluding transaction-related charges, of approximately 45 percent decreased compared to approximately 46 percent in the prior year period primarily due to the higher costs, which were mostly offset by higher pricing, as discussed above.

### Selling, general and administrative expenses

#### Three Months Ended September 30, 2019 vs. 2018

Selling, general and administrative expenses of $188.3 million decreased $6.3 million, or approximately 3 percent versus the prior year quarter. Selling, general and administrative expenses, excluding transaction-related charges, decreased to $172.3 million primarily due to cost discipline, a $5.4 million, or approximately 3 percent, decrease.

#### Nine Months Ended September 30, 2019 vs. 2018

Selling, general and administrative expenses of $569.1 million decreased $18.3 million, or approximately 3 percent versus the prior year period. Approximately $12 million of this decrease was due to lower transaction-related charges. Selling, general and administrative expenses, excluding transaction-related charges, decreased $6.2 million, or approximately 1 percent, versus the prior year period.

### Research and development expenses

#### Three Months Ended September 30, 2019 vs. 2018

Research and development expenses of $77.4 million increased $7.3 million, or approximately 10 percent versus the prior year period primarily due to higher global spending.

#### Nine Months Ended September 30, 2019 vs. 2018

Research and development expenses of $221.7 million increased $10.8 million, or approximately 5 percent versus the prior year period. The increase was primarily due to continued investments in our global discovery and product development.

### Adjusted EBITDA (Non-GAAP)

#### Three Months Ended September 30, 2019 vs. 2018

Adjusted EBITDA of $219.3 million increased $32.8 million, or approximately 18 percent versus the prior year quarter. The increase was due to higher pricing across all regions and strong volume demand as discussed above which contributed approximately 20 percent each to the increase. These factors more than offset the higher costs, primarily driven by higher raw material costs, which impacted the change in Adjusted EBITDA by approximately 22 percent.

#### Nine Months Ended September 30, 2019 vs. 2018

Adjusted EBITDA of $900.5 million increased $64.9 million, or approximately 8 percent versus the prior year period. The increase was due to the strong demand which led to higher pricing and higher volumes as discussed above which contributed approximately 17 percent and 15 percent to the increase, respectively. The price increases were primarily seen in Latin America. These factors more than offset the higher costs, primarily driven by higher raw material costs, and unfavorable foreign currency fluctuations which impacted the change in Adjusted EBITDA by approximately 17 percent and 7 percent, respectively.

For 2019, full-year Adjusted EBITDA is expected to be in the range of $1.20 billion to $1.22 billion. Although we provide a forecast for Adjusted EBITDA, a Non-GAAP financial measure, we are not able to forecast the most directly comparable measure calculated and presented in accordance with U.S. GAAP. Certain elements of the composition of the U.S. GAAP amount are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to, restructuring, acquisition charges, and discontinued operations. As a result, no U.S. GAAP outlook is provided.

### Other Results of Operations

### Depreciation and amortization

#### Three Months Ended September 30, 2019 vs. 2018

Depreciation and amortization of $36.6 million decreased $1.2 million, or approximately 3 percent, as compared to the prior year period of $37.8 million.

Nine Months Ended September 30, 2019 *vs. 2018*

Depreciation and amortization of $111.1 million slightly decreased as compared to the prior year period of $111.4 million.

### Interest expense, net

#### Three Months Ended September 30, 2019 vs. 2018

Interest expense, net of $41.6 million increased compared to the third quarter in 2018 of $33.4 million. The increase was driven by higher commercial paper balances, which were used for working capital purposes, and foreign debt which contributed approximately $4 million and $6 million, respectively. These were partially offset by lower interest expense, net due to the paydown of the 2014 Term Loan in 2018 and other items of approximately $2 million.

#### Nine Months Ended September 30, 2019 vs. 2018

Interest expense, net of $115.6 million increased compared to the prior year period of $101.7 million. The increase was driven by higher commercial paper balances, which were used for working capital purposes, and foreign debt which contributed approximately $12 million and $10 million, respectively. These were partially offset by lower interest expense, net due to the paydown of the 2014 Term Loan in 2018 and other items of approximately $8 million.

### Corporate special charges (income)

#### Restructuring and other charges (income)

*(in Millions)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Restructuring charges | $2.6 | $24.8 | $14.9 | $104.2 |
| Other charges (income), net | 4.2 | 0.6 | 12.4 | (77.8) |
| **Total restructuring and other charges (income)** | **$6.8** | **$25.4** | **$27.3** | **$26.4** |

#### Three Months Ended September 30, 2019 vs. 2018

Restructuring charges in 2019 of $2.6 million comprised of charges associated with the continued integration of the DuPont Crop Protection Business. These charges include severance, accelerated depreciation on certain fixed assets, and other costs (benefits).

Restructuring charges in 2018 of $24.8 million primarily consists of restructuring charges associated with the integration of the DuPont Crop Protection Business. There were $14.9 million of charges incurred as a continuation of our decision to exit the Ewing R&D center. Additionally, $1.8 million of restructuring charges relate to a continuation of charges as a result of the change in our market access model in India. Other restructuring charges as we continue to integrate the acquired DuPont Crop Protection Business totaled to $3.3 million.

Other charges, net in 2019 of $4.2 million primarily consists of charges of continuing environmental sites treated as a Corporate charge.

Other charges, net in 2018 of $0.6 million consists of $2.2 million of environmental related charges for remediation activities and $0.6 million of other charges associated with the divestment of a joint venture. These charges are offset by a net gain of $2.2 million on the sale of certain products of our India portfolio to Crystal Crop Protection Limited and a portion of our European herbicide portfolio to Nufarm Limited, required by regulatory authorities as part of closing conditions for the DuPont acquisition.

#### Nine Months Ended September 30, 2019 vs. 2018

Restructuring charges in 2019 of $14.9 million primarily comprised of charges associated with the continued integration of the DuPont Crop Protection Business. These charges include severance, accelerated depreciation on certain fixed assets, and other costs (benefits) of $13.2 million. There were other miscellaneous restructuring charges of $1.7 million.

Restructuring charges in 2018 of $104.2 million consists of restructuring charges associated with the integration of the DuPont Crop Protection Business of $92.5 million. These charges primarily consisted of $57.2 million of charges related to the change in our market access model in India and $27.5 million of charges due to our decision to exit the Ewing R&D as discussed above. There were other restructuring charges of $11.7 million.

Other charges, net in 2019 of $12.4 million primarily consists of charges of continuing environmental sites treated as a Corporate charge.

Other income, net in 2018 of $77.8 million primarily consists of a gain on sale of $87.2 million from the divestment of a portion of FMC's European herbicide portfolio to Nufarm Limited and certain products of our India portfolio to Crystal Crop Protection Limited. This divestiture satisfied FMC's commitment to the European Commission for regulatory requirements in order to complete the DuPont Crop Protection Acquisition. The remaining other charges represents $8.8 million of environmental related charges for remediation activities and $0.6 million associated with the divestment of a joint venture.

#### Non-operating pension and postretirement charges (income)

Income for the three months ended September 30, 2019 and 2018 was $1.2 million. Non-operating pension and postretirement charges remained flat compared to the prior year period as the higher costs, primarily due to interest costs, were offset by the lower recognized net actuarial and other (gain) loss. See Note 16 to the condensed consolidated financial statements included in this Form 10-Q for more information. Our U.S. qualified pension plan reached fully funded status during 2018. The primary investment strategy is a liability hedging approach with an objective of maintain the funded status of the plan such that the funded status volatility is minimized.

Charges for the nine months ended September 30, 2019 were $5.5 million compared to income of $0.5 million for the nine months ended September 30, 2018. The increase in expense was due to a lower expected return on plan assets of $7.4 million due to the change in investment strategy discussed above, partially offset by lower recognized net actuarial and other (gain) loss of $3.5 million.

#### Transaction-related charges

A detailed description of the transaction-related charges is included in Note 5 to the condensed consolidated financial statements included within this Form 10-Q.

### Provision for income taxes

A significant amount of our earnings are generated by foreign subsidiaries and taxed at lower statutory rates than the United States federal statutory rate (e.g., Singapore, Hong Kong, and Switzerland). Our future effective tax rates may be materially impacted by numerous items including: a future change in the composition of earnings from foreign and domestic tax jurisdictions, as earnings in foreign jurisdictions are typically taxed at more favorable rates than the United States federal statutory rate; accounting for uncertain tax positions; business combinations; expiration of statute of limitations or settlement of tax audits; changes in valuation allowance; changes in tax rates or laws; and the potential decision to repatriate certain future foreign earnings on which United States or foreign withholding taxes have not been previously accrued.

#### Three Months Ended September 30, 2019 vs. 2018

Provision for income taxes for the three months ended September 30, 2019 was $8.7 million resulting in an effective tax rate of 7.3 percent. Provision for income taxes for the three months ended September 30, 2018 was $22.0 million resulting in an effective tax rate of 30.2 percent.

*(in Millions)*

|  | Three Months Ended September 30, 2019 Income (Expense) | Tax Provision (Benefit) | Effective Tax Rate | 2018 Income (Expense) | Tax Provision (Benefit) | Effective Tax Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| **GAAP - Continuing operations** | $119.5 | $8.7 | 7.3% | $72.9 | $22.0 | 30.2% |
| Corporate special charges (income) | 21.6 | (0.8) |  | 42.4 | 8.9 |  |
| Tax adjustments (1) |  | 9.9 |  |  | (14.3) |  |
| **Non-GAAP - Continuing operations** | **$141.1** | **$17.8** | **12.6%** | **$115.3** | **$16.6** | **14.4%** |

(1) Refer to Note 3 of the *Adjusted Earnings Reconciliation* table within this section of this Form 10-Q for an explanation of tax adjustments.

#### Nine Months Ended September 30, 2019 vs. 2018

Provision for income taxes for the nine months ended September 30, 2019 was $75.6 million resulting in an effective tax rate of 12.8 percent. Provision for income taxes for the nine months ended September 30, 2018 was $81.4 million resulting in an effective tax rate of 17.6 percent.

*(in Millions)*

|  | Nine Months Ended September 30, 2019 Income (Expense) | Tax Provision (Benefit) | Effective Tax Rate | 2018 Income (Expense) | Tax Provision (Benefit) | Effective Tax Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| **GAAP - Continuing operations** | $588.4 | $75.6 | 12.8% | $462.3 | $81.4 | 17.6% |
| Corporate special charges (income) | 85.4 | 12.0 |  | 160.2 | 36.6 |  |
| Tax adjustments (1) |  | 10.1 |  |  | (18.0) |  |
| **Non-GAAP - Continuing operations** | **$673.8** | **$97.7** | **14.5%** | **$622.5** | **$100.0** | **16.1%** |

(1) Refer to Note 3 of the *Adjusted Earnings Reconciliation* table within this section of this Form 10-Q for an explanation of tax adjustments.

The primary drivers for the decrease in both the quarter-to-date and year-to-date effective tax rates for 2019 compared to 2018 are shown in the table above. The remaining change was due to the mix of earnings among subsidiaries.

### Discontinued operations, net of income taxes

Our discontinued operations include results of our discontinued FMC Lithium segment, in periods up to its separation on March 1, 2019, as well as adjustments to retained liabilities from other previously discontinued operations. The primary liabilities retained include environmental liabilities, other postretirement benefit liabilities, stock compensation, self-insurance, long-term obligations related to legal proceedings and historical restructuring activities.

#### Three Months Ended September 30, 2019 vs. 2018

Discontinued operations, net of income taxes represented a loss of $21.3 million for the three months ended September 30, 2019 compared to income of $23.9 million for the three months ended September 30, 2018. The prior year period includes a full quarter of results from our discontinued FMC Lithium segment.

#### Nine Months Ended September 30, 2019 vs. 2018

Discontinued operations, net of income taxes representing a loss of $29.8 million for the nine months ended September 30, 2019 decreased compared to income of $96.0 million for the nine months ended September 30, 2018. During the nine months ended September 30, 2019, we finalized the sale of the first of two parcels of land of our discontinued site in Newark, California and recorded a gain of approximately $21 million, net of tax. The gain on sale was fully offset by results of our discontinued FMC Lithium segment, which was a net loss due to separation-related costs, as well as charges from other previously discontinued operations. Discontinued operations, net of income taxes for the nine months ended September 30, 2018 includes an additional gain on sale of the FMC Health and Nutrition business to DuPont of approximately $17 million as a result of the adjustment to the final working capital. The prior year period also includes three full quarters of results from our discontinued FMC Lithium segment as compared to two months during 2019. Refer to Note 12 to the condensed consolidated financial statements included within this Form 10-Q for further information.

### Net income (loss)

#### Three Months Ended September 30, 2019 vs. 2018

Net income (loss) increased to $89.5 million from income of $74.8 million in the prior-year quarter. The increase was primarily due to higher gross margins due to higher revenues in the current period partially offset by the absence of income from discontinued operations related to FMC Lithium.

#### Nine Months Ended September 30, 2019 vs. 2018

Net income (loss) increased to $483.0 million from income of $476.9 million in the prior-year period. The increase was mostly driven by higher gross margins due to higher revenues in the current period partially offset by the absence of income from discontinued operations related to FMC Lithium.

### LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents at September 30, 2019 and December 31, 2018, were $419.7 million and $134.4 million, respectively. Of the cash and cash equivalents balance at September 30, 2019, $115.0 million were held by our foreign subsidiaries. The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries’ operating activities and future foreign investments. We have not provided income taxes for other additional outside basis differences inherent in our investments in subsidiaries because the investments are essentially permanent in duration or we have concluded that no additional tax liability will arise upon disposal or remittance. Determining the amount of unrecognized deferred tax liability related to permanent undistributed foreign earnings is not practicable due to the complexity of the hypothetical calculation.

At September 30, 2019, we had total debt of $3,586.0 million as compared to $2,692.7 million at December 31, 2018. Total debt included $3,032.4 million and $2,145.0 million of long-term debt (excluding current portions of $379.9 million and $386.0 million) at September 30, 2019 and December 31, 2018, respectively. As of September 30, 2019, we were in compliance with all of our debt covenants. See Note 11 in the condensed consolidated financial statements included in this Form 10-Q for further details.

Short-term debt, which consists of borrowings under our commercial paper program as well as short-term foreign borrowings, increased from $547.7 million at December 31, 2018 to $553.6 million at September 30, 2019. The increase was primarily due to higher foreign debt balances which was almost offset by the decrease in commercial paper. At September 30, 2019, we had no of borrowings under the commercial paper program.

### Senior Notes

On September 20, 2019, we issued $500 million aggregate principal amount of 3.200% Senior Notes due 2026, $500 million aggregate principal amount 3.450% Senior Notes due 2029, and $500 million aggregate principal amount 4.500% Senior Notes due 2049. A portion of the net proceeds from the offering were used for paydowns of outstanding commercial paper, 2017 Term Loan Facility balances, and general corporate purposes. We intend to use the remaining net proceeds of approximately $300 million to redeem all of our Senior notes maturing in the fourth quarter of 2019.

Fees incurred to secure the senior notes have been deferred and will be amortized over the terms of the arrangement.

See Note 18 for details on the interest rate swap settlement which will also be amortized over the terms of the arrangement.

### Revolving Credit Facility

On May 17, 2019, we entered into an amended and restated credit agreement (the "Revolving Credit Agreement"). The unsecured Revolving Credit Agreement provides for a $1.5 billion revolving credit facility, $400 million of which is available for the issuance of letters of credit for the account of the Revolving Borrowers and $50 million of which is available for swing loans to certain of the Revolving Borrowers, with an option, subject to certain conditions and limitations, to increase the aggregate amount of the revolving credit commitments to $2.25 billion (the “Revolving Credit Facility”). The current termination date of the Revolving Credit Facility is May 17, 2024.

Revolving loans under the Revolving Credit Agreement will bear interest at a floating rate, which will be a base rate or a Eurocurrency rate equal to the London interbank offered rate for the relevant interest period, plus, in each case, an applicable margin, as determined in accordance with the provisions of the Revolving Credit Agreement. The base rate will be the highest of: the rate of interest announced publicly by Citibank, N.A. in New York, New York from time to time as its “base rate”; the federal funds effective rate plus 1/2 of 1%; and the Eurocurrency rate for a one-month period plus 1%. The Company is required to pay a facility fee on the average daily amount (whether used or unused) of each Revolving Credit Lender’s revolving credit commitment from the effective date for such Revolving Credit Lender until the termination date of such Revolving Credit Lender at a rate per annum equal to an applicable percentage in effect from time to time for the facility fee, as determined in accordance with the provisions of the Revolving Credit Agreement. The initial facility fee is 0.125% per annum. The applicable margin and the facility fee are subject to adjustment as provided in the Revolving Credit Agreement.

The Revolving Credit Agreement contains customary financial and other covenants, including a maximum leverage ratio and minimum interest coverage ratio.

Fees incurred to secure the Revolving Credit Facility have been deferred and will be amortized over the term of the arrangement.

### Statement of Cash Flows

*Cash provided (required) by operating activities of continuing operations was $65.8 million and $380.3 million for the nine months ended September 30, 2019 and 2018, respectively.*

*(in Millions)*

| 2019 | Nine Months Ended September 30, 2018 |  |
| --- | ---: | ---: |
| Income from continuing operations before equity in (earnings) loss of affiliates, non-operating pension and postretirement charges (income), interest expense, net and income taxes | $709.5 | $563.4 |
| Restructuring and other charges (income), transaction-related charges and depreciation and amortization | 191.0 | 272.1 |
| **Operating income before depreciation and amortization (Non-GAAP)** | **$900.5** | **$835.5** |
| Change in trade receivables, net (1) | 118.7 | 114.7 |
| Change in inventories (2) | (151.8) | (112.2) |
| Change in accounts payable (3) | (119.4) | 103.9 |
| Change in accrued customer rebates (4) | 186.2 | 304.4 |
| Change in advance payments from customers (5) | (439.1) | (348.2) |
| Change in all other operating assets and liabilities (6) | (110.0) | (185.1) |
| **Operating cash flows (Non-GAAP)** | **$385.1** | **$713.0** |
| Restructuring and other spending (7) | $(15.3) | $(16.2) |
| Environmental spending, continuing, net of recoveries (8) | (8.7) | (9.0) |
| Pension and other postretirement benefit contributions (9) | (9.8) | (34.1) |
| Net interest payments (10) | (114.4) | (98.4) |
| Tax payments, net of refunds (10) | (109.6) | (94.2) |
| Transactional-related legal and professional fees (11) | (61.5) | (80.8) |
| **Cash provided (required) by operating activities of continuing operations** | **$65.8** | **$380.3** |

(1) Both periods include the impacts of seasonality and the receivable build intrinsic in our business. The change in cash flows related to trade receivables in 2019 was driven by timing of collections. Collection timing is more pronounced in certain countries such as Brazil where there may be terms significantly longer than the rest of our business. Additionally, timing of collection is impacted as amounts for both periods include carry-over balances remaining to be collected in Latin America, where collection periods are measured in months rather than weeks. During the nine months ended September 30, 2019, we collected approximately $743 million of receivables in Brazil.

(2) Changes in inventory are a result of inventory levels being adjusted to take into consideration the change in market conditions. Additionally, there was lower cash use for inventory in the prior year period, given inventory levels in the acquired DuPont Crop Protection Business at acquisition.

(3) The change in cash flows related to accounts payable is primarily due to timing of payments made to suppliers and vendors. Timing in 2019 was significantly impacted from global supply chain issues, primarily in China, which required us to obtain raw materials on payment terms shorter than normal. Additionally, in the prior year period there was a significant increase in account payables associated with the ramp-up of the acquired DuPont Crop Protection Business post acquisition.

(4) These rebates are primarily associated within North America and Brazil and generally settle in the fourth quarter of each year. The changes year over year are associated with the mix in sales eligible for rebates and incentives in 2019 compared to 2018 and timing of rebate payments.

(5) Advance payments are primarily associated within North America and these payments are received in the fourth quarter of each year and recorded as deferred revenue on the balance sheet at December 31. Revenue associated with advance payments is recognized, generally in the first half of each year, as shipments are made and control to the customer takes place.

(6) Changes in all periods presented primarily represent timing of payments associated with all other operating assets and liabilities, including guarantees issued to vendors under our vendor finance program. Additionally, both periods include the effects of the unfavorable contracts amortization of approximately $93 million and $66 million, respectively.

(7) See Note 10 in our condensed consolidated financial statements included in this Form 10-Q for further details.

(8) The amounts represent environmental remediation spending at our operating sites which were recorded against pre-existing reserves, net of recoveries.

(9) There were $7.0 million and $30.0 million in voluntary contributions to our U.S. qualified defined benefit plan in the periods presented in 2019 and 2018, respectively.

(10) Amounts shown in the chart represent net payments of our continuing operations.

(11) Represents payments for legal and professional fees associated with the DuPont's Crop Protection Business Acquisition. See Note 5 to the condensed consolidated financial statements included in this Form 10-Q for more information.

*Cash provided (required) by operating activities of discontinued operations was $(36.2) million and $33.7 million for the nine months ended September 30, 2019 and 2018, respectively.*

Cash provided (required) by operating activities of discontinued operations is directly related to environmental, other postretirement benefit liabilities, stock compensation, self-insurance, long-term obligations related to legal proceedings and historical restructuring activities. Both periods include the operating activities related to our discontinued FMC Lithium segment, however, the current period only includes two months of operating activities. 2018 includes divestiture cost activity related to the discontinued FMC Health and Nutrition segment.

*Cash provided (required) by investing activities of continuing operations was $(119.5) million and $23.5 million for the nine months ended September 30, 2019 and 2018, respectively.*

The change in cash from investing activities of continuing operations during the nine months ended September 30, 2019, as compared to the same period in 2018, was primarily due to proceeds from the sales of our product portfolio of approximately $88 million in the prior period that were required to complete the DuPont Crop Protection Business Acquisition that did not recur. Additionally, there was higher capital expenditure spending and capitalizable corporate level spending associated with the implementation of a new SAP system in the current period.

*Cash provided (required) by investing activities of discontinued operations was $9.2 million and $(61.0) million for the nine months ended September 30, 2019 and 2018, respectively.*

Cash provided by investing activities of discontinued operations for the nine months ended September 30, 2019 represents the proceeds from the sale of the first of two parcels of land of our discontinued site in Newark, California partially offset by capital expenditures of our discontinued FMC Lithium segment. Cash required by investing activities of discontinued operations for the nine months ended September 30, 2018 includes the final working capital payment associated with the divestiture of FMC Health and Nutrition as well as capital expenditures of our discontinued FMC Lithium segment.

*Cash provided (required) by financing activities of continuing operations was $374.8 million and $(485.5) million for the nine months ended September 30, 2019 and 2018, respectively.*

The change period over period in financing activities of continuing operations is primarily due to the proceeds from the Senior Notes partially offset by higher repurchases of common stock, repayment of long-term debt, and dividend payments in the current period as compared to the prior period.

*Cash provided (required) by financing activities of discontinued operations was $(37.2) million and zero for the nine months ended September 30, 2019 and 2018, respectively.*

Cash required by financing activities of discontinued operations for the nine months ended September 30, 2019 represents debt repayments on FMC Lithium's external debt as well as cash payments associated with the separation of FMC Lithium.

### Other potential liquidity needs

Our cash needs outside of the DuPont Crop Protection Business related integration expenses for 2019 include operating cash requirements (which include funding of seasonal working capital), capital expenditures, scheduled mandatory payments of long-term debt, dividend payments, share repurchases, contributions to our pension plans, environmental and asset retirement obligation spending and restructuring. We plan to meet our liquidity needs through available cash, cash generated from operations, commercial paper issuances and borrowings under our committed revolving credit facility. At September 30, 2019, our remaining borrowing capacity under our credit facility was $1,282.8 million (which includes borrowing capacity under our commercial paper program).

Projected 2019 capital expenditures as well as expenditures related to contract manufacturers are expected to be approximately $150 million, at the midpoint of the range, primarily driven by expenditures associated with capacity expansion. Additionally, we will continue to incur spending associated with the implementation of a new SAP system.

As a result of the Act, we will continue to pay the remaining $145.6 million of transition tax over the next six years.

Projected 2019 spending includes approximately $75 million to $80 million of net environmental remediation spending at both our continuing and discontinued sites. This projected spending for 2019 includes spending as a result of an agreed Order on Consent and Administrative Settlement primarily to address discontinued operations at our Middleport, New York site. This projected spending does not include expected spending on capital projects relating to environmental control facilities or expected spending for environmental compliance costs, which we will include as a component of "Costs of sales and services" in our condensed consolidated statements of income (loss) since these amounts are not covered by established reserves. Capital spending to expand, maintain or replace equipment at our production facilities may trigger requirements for upgrading our environmental controls, which may increase our spending for environmental controls over the foregoing projections.

In order to reduce future funding volatility in our U.S. qualified defined benefit pension plan, we have made voluntary cash contributions of $7.0 million during the third quarter of 2019. These contributions are in excess of the minimum requirements. We do not expect to make any further contributions to our U.S. qualified defined benefit pension plan during 2019.

For the nine months ended September 30, 2019 and September 30, 2018, we paid dividends of $158.3 million and $66.9 million, respectively. On October 17, 2019, we paid dividends totaling $52.0 million to our shareholders of record as of September 30, 2019. This amount is included in “Accrued and other liabilities” on the condensed consolidated balance sheet as of September 30, 2019.

During the nine months ended September 30, 2019, 3.7 million shares were repurchased under the publicly announced repurchase program. At September 30, 2019, approximately $700 million remained unused under our Board-authorized repurchase program. We intend to purchase a total of up to $400 million of our common shares in 2019. This repurchase program does not include a specific timetable or price targets and may be suspended or terminated at any time. Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market conditions and other factors. We also reacquire shares from time to time from employees in connection with the vesting, exercise and forfeiture of awards under our equity compensation plans.

### Commitments and Contingencies

See Note 19 to the condensed consolidated financial statements included in this Form 10-Q.

### Contractual Commitments

Information related to our contractual commitments at December 31, 2018 can be found in a table included within Part II, Item 7 of our 2018 Form 10-K. There have been no significant changes to our contractual commitments during the nine months ended September 30, 2019.

### Climate Change

A detailed discussion related to climate change can be found in Part II, Item 7 of our 2018 Form 10-K.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

### Fair Value Measurements

See Note 18 to the condensed consolidated financial statements in this Form 10-Q for additional discussion surrounding our fair value measurements.

### DERIVATIVE FINANCIAL INSTRUMENTS AND MARKET RISKS

Our earnings, cash flows, and financial position are exposed to market risks relating to fluctuations in commodity prices, interest rates and foreign currency exchange rates. Our policy is to minimize exposure to our cash flow over time caused by changes in commodity, interest and currency exchange rates. To accomplish this, we have implemented a controlled program of risk management consisting of appropriate derivative contracts entered into with major financial institutions.

The analysis below presents the sensitivity of the market value of our financial instruments to selected changes in market rates and prices. The range of changes chosen reflects our view of changes that are reasonably possible over a one-year period. Market-value estimates are based on the present value of projected future cash flows considering the market rates and prices chosen.

At September 30, 2019, our financial instrument position was a net asset of $3.4 million compared to a net asset of $11.4 million at December 31, 2018. The change in the net financial instrument position was primarily due to changes in foreign exchange and interest rates.

Since our risk management programs are generally highly effective, the potential loss in value for each risk management portfolio described below would be largely offset by changes in the value of the underlying exposure.

### Commodity Price Risk

Energy costs are diversified among electricity and natural gas. We attempt to mitigate our exposure to increasing energy costs by hedging the cost of future deliveries of natural gas and electricity. To analyze the effect of changing energy prices, we perform a sensitivity analysis in which we assume an instantaneous 10 percent change in energy market prices from their levels at September 30, 2019 and December 31, 2018, with all other variables (including interest rates) held constant. Note, as of September 30, 2019 and December 31, 2018, we had no open commodity contracts. As a result, there was no sensitivity analysis performed over commodity price risk for the periods presented.

### Foreign Currency Exchange Rate Risk

The primary currencies for which we have exchange rate exposure are the U.S. dollar versus the Euro, the U.S. dollar versus the Chinese yuan, the U.S. dollar versus the Brazilian real and the U.S. dollar versus the Argentine peso. Foreign currency debt and foreign exchange forward contracts and options are used in countries where we do business, thereby reducing our net asset exposure. Foreign exchange forward contracts and options are also used to hedge firm and highly anticipated foreign currency cash flows.

To analyze the effects of changing foreign currency rates, we have performed a sensitivity analysis in which we assume an instantaneous 10 percent change in the foreign currency exchange rates from their levels at September 30, 2019 and December 31, 2018, with all other variables (including interest rates) held constant.

*(in Millions)*

|  | Net Asset / (Liability) Position on Condensed Consolidated Balance Sheets | 10% Strengthening | 10% Weakening |
| --- | ---: | ---: | ---: |
| **Net asset (liability) position at September 30, 2019** | $4.7 | $40.0 | $(39.9) |
| **Net asset (liability) position at December 31, 2018** | $11.6 | $19.2 | $(16.7) |

### Interest Rate Risk

One of the strategies that we can use to manage interest rate exposure is to enter into interest rate swap agreements. In these agreements, we agree to exchange, at specified intervals, the difference between fixed and variable interest amounts calculated on an agreed-upon notional principal amount. As of September 30, 2019, we had outstanding interest rate swap contracts in place with an aggregate notional value of $200.0 million.

To analyze the effects of changing interest rates, we have performed a sensitivity analysis in which we assume an instantaneous one percent change in the interest rates from their levels at September 30, 2019 and December 31, 2018, with all other variables held constant.

*(in Millions)*

|  | Net Asset / (Liability) Position on Condensed Consolidated Balance Sheets | 1% Increase | 1% Decrease |
| --- | ---: | ---: | ---: |
| **Net asset (liability) position at September 30, 2019** | $(1.3) | $1.0 | $(1.0) |
| **Net asset (liability) position at December 31, 2018** | $(0.2) | $2.2 | $(2.7) |

Our debt portfolio, at September 30, 2019, is composed of 82 percent fixed-rate debt and 18 percent variable-rate debt. The variable-rate component of our debt portfolio principally consists of borrowings under our 2017 Term Loan Facility, Revolving Credit Facility, commercial paper program, variable-rate industrial and pollution control revenue bonds, and amounts outstanding under foreign subsidiary credit lines. Changes in interest rates affect different portions of our variable-rate debt portfolio in different ways.

Based on the variable-rate debt in our debt portfolio at September 30, 2019, a one percentage point increase in interest rates then in effect would have increased gross interest expense by $4.8 million and a one percentage point decrease in interest rates then in effect would have decreased gross interest expense by $4.8 million for the nine months ended September 30, 2019.

## Market risk

As filed, 207 characters.

The information required by this item is provided in “Derivative Financial Instruments and Market Risks,” under ITEM 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

## Controls and procedures

As filed, 4,369 characters.

(a) Evaluation of disclosure controls and procedures. Based on management’s evaluation (with the participation of the Company’s Chief Executive Officer and Chief Financial Officer), the Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2019, the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to provide reasonable assurance that information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b) Change in Internal Controls. During the third quarter of 2019, we completed another phase of our ERP implementation by migrating our Brazil entity to the new system. As a result, we have implemented updates and changes to our current processes and related control activities. As the phased implementation continues, we will experience certain changes to our processes and procedures which, in turn, will result in changes to our internal controls over financial reporting. For a discussion of risks related to the implementation of new systems, see Part I, Item 1A "Risk Factors" of our 2018 Form 10-K.

### Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

FMC Corporation:

#### Results of Review of Interim Financial Information

We have reviewed the condensed consolidated balance sheet of FMC Corporation and subsidiaries (the Company) as of September 30, 2019, the related condensed consolidated statements of income (loss), comprehensive income (loss) and changes in equity for the three-month and nine-month periods ended September 30, 2019 and 2018, the related condensed consolidated statements of cash flows for nine-month periods ended September 30, 2019 and 2018, and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 31, 2018, and the related consolidated statements of income (loss), comprehensive income (loss), changes in equity, and cash flows for the year then ended (not presented herein); and in our report dated February 28, 2019, except with respect to the effects of reporting the FMC Lithium segment as a discontinued operation, as discussed in Note 1, as to which the date is August 2, 2019, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2018, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

#### Basis for Review Results

This consolidated interim financial information is the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

**/s/** KPMG LLP

Philadelphia, Pennsylvania

October 30, 2019

## Risk factors

As filed, 847 characters.

In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A "Risk Factors" of our 2018 Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) for the fiscal year ended December 31, 2018 and the Company’s other filings with the SEC, which are available at www.sec.gov and on the Company’s website at www.fmc.com.

### Forward-Looking Information

We wish to caution readers not to place undue reliance on any forward-looking statements contained herein, which speak only as of the date made. We specifically decline to undertake any obligation to publicly revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Filed Oct 30, 2019.
Source: SEC EDGAR, the filing index for accession 0000037785-19-000116. Last ingested by Listed: Nov 13, 2026, 16:31 ET. No prices; not investment advice.
